The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease.
ACLF
NASH
bacterial translocation
fibrosis
inflammation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
10
2019
accepted:
27
05
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
7
4
2021
Statut:
epublish
Résumé
The macrophage-inducible C-type lectin (mincle) is part of the innate immune system and acts as a pattern recognition receptor for pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces mincle activation which consequently interacts with the signaling adapter Fc receptor, SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages promotes intestinal barrier integrity. However, little is known about the role of mincle in hepatic fibrosis, especially in more advanced disease stages. Mincle expression was measured in human liver samples from cirrhotic patients and donors collected at liver transplantation and in patients undergoing bariatric surgery. Human results were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF). In these models, the role of mincle was investigated in liver samples as well as in peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine, and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB). In human NASH, mincle is upregulated with increased collagen production. In ApoE deficient mice fed high-fat western diet (NASH model), mincle activation significantly increases hepatic collagen production. In human cirrhosis, mincle expression is also significantly upregulated. Furthermore, mincle expression is associated with the stage of chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF was induced by LPS injection in cirrhotic rats. While mincle expression and downstream signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they are downregulated in PBMCs of these rats. Although mincle expressed on macrophages might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic liver disease.
Identifiants
pubmed: 32733451
doi: 10.3389/fimmu.2020.01352
pmc: PMC7358277
doi:
Substances chimiques
Biomarkers
0
Lectins, C-Type
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1352Informations de copyright
Copyright © 2020 Schierwagen, Uschner, Ortiz, Torres, Brol, Tyc, Gu, Grimm, Zeuzem, Plamper, Pfeifer, Zimmer, Welsch, Schaefer, Rheinwalt, Clària, Arroyo, Trebicka and Klein.
Références
Immun Inflamm Dis. 2017 Dec;5(4):503-514
pubmed: 28722316
Am J Pathol. 2018 Apr;188(4):967-980
pubmed: 29355515
Hepatology. 2018 Oct;68(4):1621-1632
pubmed: 29689120
Can J Gastroenterol Hepatol. 2018 Aug 1;2018:1027152
pubmed: 30155448
Biotechniques. 2004 Apr;36(4):618-20, 622, 624-6
pubmed: 15088380
Liver Int. 2016 Mar;36(3):386-94
pubmed: 26212075
Visc Med. 2018 Aug;34(4):270-275
pubmed: 30345284
J Mol Cell Cardiol. 2011 Dec;51(6):1007-14
pubmed: 21884703
Hepatology. 2007 Jul;46(1):242-53
pubmed: 17596891
Nat Commun. 2014 Sep 19;5:4982
pubmed: 25236782
Liver Int. 2018 May;38(5):875-884
pubmed: 29105936
Nat Immunol. 2007 Jun;8(6):619-29
pubmed: 17486093
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Immunity. 2019 Feb 19;50(2):446-461.e9
pubmed: 30709742
Brain Behav Immun. 2017 Feb;60:346-360
pubmed: 27845194
Front Immunol. 2019 Mar 19;10:476
pubmed: 30941129
PLoS One. 2013 Dec 11;8(12):e82163
pubmed: 24349208
Kidney Int. 2017 Mar;91(3):587-602
pubmed: 28017324
J Hepatol. 2015 Feb;62(2):332-9
pubmed: 25457205
Nat Immunol. 2007 Feb;8(2):198-205
pubmed: 17187069
Am J Physiol Gastrointest Liver Physiol. 2016 Oct 1;311(4):G724-G733
pubmed: 27634010
Front Immunol. 2019 Feb 08;10:69
pubmed: 30800122
Curr Opin Crit Care. 2011 Apr;17(2):184-9
pubmed: 21311322
Sci Rep. 2015 Aug 11;5:12931
pubmed: 26263022
Hepatology. 2016 Oct;64(4):1249-64
pubmed: 27483394
Nat Immunol. 2008 Oct;9(10):1179-88
pubmed: 18776906
J Hepatol. 2010 Oct;53(4):702-12
pubmed: 20633948
Sci Rep. 2016 Mar 15;6:23097
pubmed: 26975571
J Hepatol. 2005 Feb;42(2):195-201
pubmed: 15664244
Am J Transplant. 2008 May;8(5):1006-15
pubmed: 18416738
Hepatology. 2018 Apr;67(4):1472-1484
pubmed: 29059466
Semin Liver Dis. 2016 May;36(2):167-73
pubmed: 27172359
J Exp Med. 2009 Dec 21;206(13):2879-88
pubmed: 20008526
Hepatology. 2005 Mar;41(3):422-33
pubmed: 15723320
Nat Rev Dis Primers. 2016 Jun 09;2:16041
pubmed: 27277335
J Am Heart Assoc. 2018 Sep 4;7(17):e009384
pubmed: 30371153
Gut. 2017 Mar;66(3):507-518
pubmed: 27432540
Aliment Pharmacol Ther. 2019 Sep;50(5):568-579
pubmed: 31286545
Basic Res Cardiol. 2010 Jul;105(4):465-77
pubmed: 20361197
Nat Immunol. 2016 May;17(5):593-603
pubmed: 26950238
Hepatology. 2014 Jul;60(1):334-48
pubmed: 24619965
J Clin Exp Hepatol. 2014 Dec;4(4):302-11
pubmed: 25755577
Front Immunol. 2018 Jan 17;8:1940
pubmed: 29387054
Gut. 2019 Mar;68(3):578-580
pubmed: 29581241
Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G182-G194
pubmed: 31188634